stockrow
Friday 6 November 2026
Export NVCR’s income statement to Excel — free account
NovoCure Limited
NVCR Healthcare Medical Devices
NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +72.9%
- Free cash flow
- +5.54%
- Total debt
- +0.87%
Quarter to September 2026, against a year earlier
13.26
0.29
−2.14%
Follow NVCR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 3 | 3 | 5 |
| (38.89%) | (49.96%) | (43.22%) | (35.18%) | ||
| (13.32%) | (16.99%) | (14.56%) | (11.12%) | ||
ROIC |
(123.24%) | (92.52%) | (115.56%) | (106.10%) | |
Return on Tangible Assets |
(26.04%) | (33.69%) | (28.58%) | (24.16%) | |
Average Days of Receivables |
82.49 | 79.24 | 76.12 | 80.17 | |
Free Cash Flow per Share |
(0.68) | (0.42) | (0.22) | (0.21) | |
Free Cash Flow |
(75.68) | (48.07) | (25.43) | (24.61) | |
Capital Expenditures |
(26.65) | (21.19) | (22.62) | (23.88) | |
| Other line items | |||||
Cash ROIC |
(7.62%) | (4.77%) | (2.58%) | (2.41%) | |
Accounts Receivable Turnover |
5.09 | 5.09 | 5.09 | 5.11 | |
Accounts Payable Turnover |
1.47 | 1.50 | 1.42 | 1.26 | |
Inventory Turnover |
4.38 | 4.03 | 4.05 | 4.18 | |
Average Days of Payables |
267.35 | 277.62 | 285.86 | 319.46 | |
Days of Inventory on Hand |
89.92 | 94.82 | 92.33 | 88.90 | |
Tax Rate |
0.00 | (0.01) | (0.03) | (0.07) | |
Research and Development Expense of Revenue |
34.26% | 33.97% | 32.14% | 31.54% | |
Selling, General and Administrative Expense of Revenue |
63.74% | 68.41% | 66.07% | 62.65% | |
Share Based Compensation of Revenue |
16.00% | 20.51% | 18.47% | 16.17% | |
Interest Coverage |
8.76 | 22.52 | 90.29 | (20.76) | |
Operating CF/Net income |
0.36 | 0.16 | 0.02 | 0.01 | |
Depreciation/Fixed assets |
(0.09) | (0.04) | 0.01 | 0.05 | |
Capex/Depreciation |
3.09 | 5.61 | (23.71) | (4.34) | |
Revenue per Share |
5.88 | 5.91 | 6.03 | 6.21 | |
Operating CF per Share |
(0.44) | (0.24) | (0.02) | (0.01) | |
Capex per Share |
(0.24) | (0.19) | (0.19) | (0.20) | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 2 Nov 2026